Blog Archives


Toronto, ON, Canada – Biologic therapies are an expensive group of drugs increasingly being used to treat inflammatory diseases in children and adults. Coverage in publicly-financed drug plans has been inconsistent and, at a cost of over $17,000 per year,

Tagged with: , , , , ,
Posted in Preference-Based Assessments, Value in Health

Quality Measures Developed For Childhood Cancer Care Systems

Toronto, ON, Canada – Researchers at Pediatric Oncology Group of Ontario (POGO) and McMaster University have developed measures of the quality of childhood cancer care delivery systems. These measures will be used to evaluate the performance of the childhood cancer system in

Tagged with: , , , , , ,
Posted in Health Policy Analyses, Value in Health

Nice’s Scientific Credibility Compromised By Recent Amendment To Appraisal Methods

Toronto, ON, Canada – The National Institute for Health and Care Excellence (NICE) is highly regarded for the rigorous methods it adopts for the economic appraisal of health care technologies. A recent amendment to these appraisal methods, however, raises a number

Tagged with: , , , ,
Posted in Commentary, Value in Health

Patients Willing To Pay More For Avoiding Symptoms Of GERD

Hamilton, ON, Canada – Gastroesophageal reflux disease (GERD) affects about 25% of the population in Western countries. Patients suffer symptoms at least monthly and five percent have daily heartburn.

Tagged with: , , , ,
Posted in Preference-Based Assessments, Value in Health

Need For Speed In Value Of Information Analysis In Health Care: Some New Developments

Vancouver, Canada – Mathematical modeling has become fundamental to health technology assessment (HTA) and comparative effectiveness research. It allows comprehensive, transparent, and objective quantification of evidence in evaluating health technologies. Such models not only tell us which health technology provides the

Tagged with: , , ,
Posted in Value in Health

Drugs For Rare Diseases: How To Fund Them?

Toronto, ON, Canada– Enzyme replacement therapies for rare inherited metabolic diseases are among the most expensive drugs in the world and have created a dilemma for public drug payers.

Tagged with: , , , ,
Posted in Policy Perspectives, Value in Health
Follow ISPOR
RSS FeedFriend me on FacebookFollow my company on LinkedInFollow me on TwitterWatch me on YouTube